The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
LRRK2 Cohort Consortium Resource Request, 2013Alpha-synuclein and Other Biomarkers in Biological Samples of LRRK2 Parkinson’s Disease
Objective/Rationale:
Cerebrospinal fluid (CSF) biomarkers of Alzheimer’s pathology have been investigated in Parkinson’s disease (PD), and abnormal CSF protein levels (tau and phosphorylated tau, beta... -
Dyskinesia Challenge, 2013NOP Receptor Agonists for Preventing Levodopa-induced Dyskinesia
Objective/Rationale:
Dyskinesia (involuntary fractured, jerky movements) is a debilitating side effect of long-term levodopa treatment for Parkinson’s motor symptoms. Previous studies have... -
Therapeutic Pipeline Program, 2013Novel, Small Molecule Transforming Growth Factor Beta Agonist
Objective/Rationale:
This project aims to develop a small molecule-based therapeutic targeting transforming growth factor beta (TGFB) signaling for the treatment of Parkinson’s disease (PD... -
LRRK2 Pharmacodynamic Assays, 2013Measuring LRRK2 Cellular Function in Parkinson’s iPSC-Derived Dopaminergic Neurons
Objective/Rationale:
We aim to develop a time-lapse, imaging, pharmacodynamic assay for measuring LRRK2 cellular function in dopaminergic (DA) neurons derived from human induced... -
Research Grant, 2013Alpha-Synuclein-Expression-Lowering Therapeutics: Initial Pre-Clinical Development
Objective/Rationale:
Increased dosage of the alpha-synuclein gene is linked to Parkinson’s disease (PD). Out of 1,126 FDA-approved compounds and health supplements screened, we identified... -
Rapid Response Innovation Awards, 2013BL-OG: A Novel, Minimally-Invasive and Homeostatic Method for Selective Regulation of Neural Dynamics in the Subthalamic Nucleus
Objective/Rationale:
Altered neural activity in the subthalamic nucleus (STN) is believed to be key to Parkinson’s disease. Accordingly, deep-brain stimulation (DBS) delivered to the STN...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.